Aaron N. Cranston
Cambridge Institute for Medical Research
Cancer Research UK Department of Oncology
University of Cambridge
Hills Road
UK
Name/email consistency: high
- A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation. Cranston, A., Carniti, C., Martin, S., Mondellini, P., Hooks, Y., Leyland, J., Hodgson, S., Clarke, S., Pierotti, M., Ponder, B.A., Bongarzone, I. Mol. Endocrinol. (2006)
- RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cranston, A.N., Carniti, C., Oakhill, K., Radzio-Andzelm, E., Stone, E.A., McCallion, A.S., Hodgson, S., Clarke, S., Mondellini, P., Leyland, J., Pierotti, M.A., Whittaker, J., Taylor, S.S., Bongarzone, I., Ponder, B.A. Cancer Res. (2006)
- Quantitative phenotyping as an efficient means to estimate C-cell number in a knock-in mouse model of MEN2B. Cranston, A., Howard, L., Howard, C.V. Transgenic Res. (2004)
